Diabetes, Hypertension, and Cardiovascular Disease: Clinical Insights and Vascular Mechanisms.
Petrie JR, Guzik TJ, Touyz RM. · 2018
Read Diabetes, Hypertension, and Cardiovascular Disease: Clinical Insights and Vascular Mechanisms. by Petrie JR, Guzik TJ, Touyz RM. (2018) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5953551.txt.
Introduction
Petrie, Guzik, and Touyz review diabetes, high blood pressure, and heart disease as linked ills. Their review was published in the Canadian Journal of Cardiology. High blood pressure is twice as common in people with diabetes. People with high blood pressure often resist insulin as well. Heart and vessel disease is the top cause of death in diabetes. High blood pressure makes that load worse.
The two ills share risk factors and roots, the authors explain. These take in stiff vessel walls and sore, swollen tissue. A shared hormone system, cell rust, and immune stir also play a part. The review takes in sugar-damaged proteins and small gene bits. It ends with drug care now and new vessel guards.
Catalog record
| CREATOR | Petrie JR, Guzik TJ, Touyz RM. |
|---|---|
| YEAR | 2018 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 56 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Diabetes, Hypertension, and Cardiovascular Disease: Clinical Insights and Vascular Mechanisms By John R. Petrie, Tomasz J. Guzik, Rhian M. Touyz Published in: The Canadian Journal of Cardiology DOI: 10.1016/j.cjca.2017.12.005 ABSTRACT Hypertension and type 2 diabetes are common comorbidities. Hypertension is twice as frequent in patients with diabetes compared with those who do not have diabetes. Moreover, patients with hypertension often exhibit insulin resistance and are at greater risk of diabetes developing than are normotensive individuals. The major cause of morbidity and mortality in diabetes is cardiovascular disease, which is exacerbated by hypertension. Accordingly, diabetes and hypertension are closely interlinked because of similar risk factors, such as endothelial dysfunction, vascular inflammation, arterial remodelling, atherosclerosis, dyslipidemia, and obesity. There is also substantial overlap in the cardiovascular complications of diabetes and hypertension related primarily to microvascular and macrovascular disease. Common mechanisms, such as upregulation of the renin-angiotensin-aldosterone system, oxidative stress, inflammation, and activation of the immune system likely contribute to the close relationship between diabetes and hypertension. In this article we discuss diabetes and hypertension as comorbidities and discuss the pathophysiological features of vascular complications associated with these conditions. We also highlight some vascular mechanisms that predispose to both conditions, focusing on advanced glycation end products, oxidative stress, inflammation, the immune system, and microRNAs. Finally, we provide some insights into current therapies targeting diabetes and cardiovascular complications and introduce some new agents that may have vasoprotective therapeutic potential in diabetes. TYPE 2 DIABETES MELLITUS AND HYPERTENSION The prevalence of obesity and type 2 diabetes (T2D) continues to rise worldwide as lifestyles associated with low energy expenditure and high caloric intake are increasingly adopted, particularly in lower-income and developing countries. It is predicted that the number of cases of T2D will rise from 415 million to 642 million by 2040.1 Hypertension is even more common, rising in prevalence in the same countries, with a recent worldwide estimate of 1.39 billion cases.2 Although T2D and hypertension can be simply diagnosed at the bedside, they are each complex and heterogeneous phenotypes associated with an elevated risk of life-threatening cardiovascular disease (CVD). Their frequent coexistence in the same individual is not a coincidence, because aspects of the pathophysiology are shared by both conditions, particularly those related to obesity and insulin resistance. For example, in the San Antonio Heart Study, 85% of those with T2D had hypertension by the fifth decade of life, whereas 50% of those with hypertension experienced impaired glucose tolerance or T2D.3 In health, insulin maintains glucose homeostasis by integrated actions on carbohydrate, protein, and lipid metabolism. Loss of sensitivity to aspects of insulin action (insulin resistance) principally affects the liver, muscle, and adipose tissues and is selective for glucose and lipid metabolism, eg, sparing insulin's action to retain sodium in the distal tubule.4, 5 Reduction in insulin-mediated glucose disposal leads to compensatory hypersecretion of insulin to maintain homeostasis: Glucose intolerance ensues if this endocrine pancreas response is inadequate, although some obese individuals avoid T2D by virtue of a supranormal B-cell response.6 Recently, the role of adipose tissue in these associations has been increasingly appreciated.7 Diabetes is associated with both macrovascular (involving large arteries such as conduit vessels) and microvascular (involving small arteries and capillaries) disease. Chronic hyperglycemia and insulin resistance play an important role in the initiation of vascular complications of diabetes and involve a number of mechanisms including (1) increased formation of advanced glycation end products (AGEs) and activation of the receptor for advanced glycation end products (RAGE) AGE-RAGE axis, (2) oxidative stress, and (3) inflammation.8 In addition, emerging evidence suggests a role for microRNAs (miRNAs) in the vasculopathy of diabetes (see further on).9 Hypertension is an important risk factor for diabetes-associated vascular complications, because hypertension itself is characterized by vascular dysfunction and injury (Fig. 1).Figure 1Vascular processes whereby diabetes and hypertension predispose to cardiovascular disease. Common risk factors promote diabetes and hypertension, which are associated with atherosclerosis, vascular inflammation, endothelial dysfunction, and structural remodelling, which lead to macrovascular and microvascular disease. Vascular damage and endothelial dysfunction is amplified when diabetes and hypertension coexist. In this review, we focus on vascular complications of diabetes and discuss the impact of comorbidities, specifically hypertension. The role of oxidative stress and inflammation as “common soil” for metabolic and vascular disease are highlighted. We also discuss how some of the newer agents used in the treatment of T2D can influence blood pressure (BP) regulation and the risk of CVD, with an eye to future developments more specifically targeting vascular protection. MACROVASCULAR DISEASE Clinical features Macrovascular (or cardiovascular) disease of larger conduit arteries is a complex inflammatory process leading to myocardial infarction, stroke, and peripheral artery disease. The primary pathologic process associated with macrovascular disease is atherosclerosis, which in diabetes is accelerated with extensive distribution of vascular lesions.10 T2D confers an approximate 2-fold elevation in CVD risk, equivalent to that of a previous myocardial infarction.11, 12 Moreover, patients with T2D have poorer outcomes after an acute coronary syndrome and higher rates of reinfarction and heart failure.13 Elevation of CVD risk begins at the stage of prediabetes in association with insulin resistance and impaired glucose tolerance.14 As well as being the diagnostic hallmark of T2D, hyperglycemia is the principal determinant of microvascular complications of T2D and plays an important role in the pathogenesis of CVD. However, in established T2D, it is a relatively weak modifiable risk factor compared with hypertension, dyslipidemia, and (unfortunately in many populations) cigarette smoking.15, 16 Pathophysiological features Insulin resistance is detectable for several years before the onset of T2D. It is associated with obesity, particularly central obesity, but may be present in lean individuals with hypertension.17 During calorie excess, adipocytes in obese humans—whether in subcutaneous or visceral areas—undergo hypertrophy. Visceral adipocytes are more susceptible to cellular death as they begin to enlarge and their stromal vascular fraction becomes infiltrated with macrophages.18 These macrophages around dead adipocytes form “crown-like structures,” a histologic appearance that is associated with expression of cytokines (including tumor necrosis factor-α [TNF-α], interleukin-6 [IL-6]), and inducible nitric oxide synthase.19 These changes have been shown to coincide with the onset of insulin resistance and provide a pathophysiological link between metabolic and vascular disease.20 In addition to these proinflammatory changes, adipocyte hypertrophy is associated with larger triglyceride stores, a higher lipolytic rate, and an atherogenic lipid profile: elevated concentrations of small dense low-density lipoprotein cholesterol, high concentrations of triglycerides, triglyceride-rich remnants, very low-density lipoprotein cholesterol, and apolipoprotein B, usually in combination with low levels of high-density lipoprotein cholesterol.7 This profile is associated with increased production of leptin, decreased production of adiponectin, higher circulating levels of nonesterified fatty acids (NEFAs), and activation of mitochondrial oxidative stress pathways in vascular endothelial cells.7 These proinflammatory and metabolic consequences of obesity and insulin resistance result in endothelial dysfunction, a key antecedent and modulator of atherosclerosis that has been demonstrated not only in hypertension but also in prediabetes,21 first-degree relatives of individuals with T2D,22 and even insulin-resistant healthy individuals.22, 23 It is characterized by disruption of the intricate physiological balance between vasoconstrictors (endothelin, angiotensin II) and vasodilators (nitric oxide, prostacyclin), growth promoting and inhibitory factors, proatherogenic and antiatherogenic factors, and procoagulant and anticoagulant factors.24, 25 A substantial body of evidence suggests that impaired endothelium-dependent vasodilation may in turn contribute to